| Abstract |
[Abstract] Objective To analyze the incidence and risk factors of metabolic syndrome (MS) in hospitalized patients with schizophrenia. Method: Total of 100 patients with schizophrenia during November 2022 to November 2024 and were divided into two groups based on patient’s behavior of metabolic syndrome (MS), and were named as the MS group and the non-MS group. The demographic, laboratory, and disease-related indicators between two groups of patients, assign values to data with significant differences between groups were compared, and multivariate analysis were conducted. Results: Total 100 patients with schizophrenia, 33 developed MS There were significant differences in age, admission body mass index, chlorpromazine equivalent dose, total cholesterol(TC)、fasting plasma glucose(FPG), disease duration, education time, positive and negative syndrome scale (PANSS), and hospitalization frequency between the MS group and the non-MS group (P<0.05). There was no statistically significant difference in residence, smoking history, and alcohol consumption history between the two groups (P>0.05). Multivariate analysis found that age, admission body mass index, equivalent dose of chlorpromazine, TC, and FPG were risk factors for MS (P<0.05). Conclusions: Hospitalized patients with schizophrenia are prone to developing MS, and factors such as age, admission body mass index, and equivalent dose of chlorpromazine can increase the risk of MS.
|